Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05749822 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 1, 2025 to Dec 1, 2027
    • Study completion date: Dec 31, 2025 to Dec 31, 2027
    v7
  2. Study sites: 5 to 12v6
  3. Study Identification, Study Statusv5
  4. Primary completion date: Dec 1, 2024 to Dec 1, 2025
    • Study sites: 1 to 5
    v4
  5. Re-verified, no change to tracked fieldsv3
  6. Start date changed from estimate of Mar 1, 2023 to Feb 17, 2023v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (PBC).
Trial Details
NCT Number NCT05749822
Lead Sponsor Xijing Hospital of Digestive Diseases
Conditions
(from sponsor)		 Primary Biliary Cholangitis
Related terms Liver Cirrhosis, Biliary
Enrollment 104 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov